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My PhD thesis is composed of six chapters.  
In Chapter 1, general introduction including background information and objective & 
strategy of this thesis was described. 
Protein-protein interactions (PPIs) are involved in almost all cellular processes and their 
defectiveness accounts for dysregulated signaling and the resulted diseases, thus representing 
an important class of targets for the treatment of various diseases. Inhibitors of PPIs are 
crucial tools for developing therapies for human diseases. Peptides, which combine the 
favorable properties of both small molecules and protein therapeutics, represent a promising 
class of therapeutics to disrupt specific protein-protein interactions. However, it’s still 
challenging to make effective peptide inhibitors, and the generally low half-lives of peptides 
in vivo have probably caused this lack of success.  
In my study, with the aim to make peptides more effective at inhibiting specific PPIs: to 
improve their stability and to evaluate their inhibitory potency in vitro and in vivo, a 
combined strategy was employed: the strategy of bioactive sequences grafting into the 
scaffold of natural cyclic peptides was combined with the strategy of SrtA-mediated synthesis 
of grafted cyclic peptides, optimization of the grafting site and grafted sequence, as well as 
BRET-based assay. The advantages of the above strategies are as follows: peptide-grafting 
strategy provides one of the most effective routes to make peptides less susceptible to 
proteolytic degradation; SrtA can catalyze protein/peptide cyclization easily and efficiently in 
vitro, moreover, it’s promising to extend the applications of SrtA to in vivo; BRET assay is 
applicable both in vitro and in vivo. 
I first selected SFTI-1 to provide the stable scaffold for bioactive peptides grafting, 
considering its outstanding proteolytic stability, small size, and tolerance to mutagenesis. To 
explore the possibility of SFTI-1 as the scaffold for developing stable peptide inhibitors, I 
selected a tetrapeptide ESDV as the model sequence, which is known to be the starting point 
for developing drugs for the treatment of ischemic brain diseases.  
In Chapter 2, the strategy of “enzymatic synthesis of stable cyclic peptide-inhibitors of 
protein-protein interactions” was investigated in vitro. The tetrapeptide ESDV was grafted 
into the framework of SFTI-1 by replacing the original residues FPDG in the smaller loop 
which is suggested to be a “plug and play” cassette. The head-to-tail cyclization of the grafted 
peptide was catalyzed by SrtA, after assembled with the recognition sequences of SrtA.  
It shows that cyclization of the grafted peptide catalyzed by SrtA proceeded efficiently, 
and the cyclic peptide was obtained in good yield. The produced cyclic peptide showed 
significantly enhanced stability against proteolytic degradation, with half life longer than 20 h 
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in human serum. Interestingly, it is found that SFTI-1 scaffold even without a cyclic 
backbone could provide stability to a grafted peptide, likely due to the extra stability 
conferred by the hydrogen bond network, disulfide bond as well as the constrained structure 
of the scaffold. It is thus concluded that peptide sequences can be stabilized by grafting into 
SFTI-1 scaffold. 
However, in the case of ESDV motif, peptide grafting and cyclization result in reduced 
binding ability to PDZ2 domain of PSD-95. By SPR analysis, the interaction between the 
cyclic peptide and PDZ2 domain could be clearly detected, but when the binding ability of the 
cyclic peptide to immobilized PDZ2 was compared with that of Tat-NR2B9c, which has been 
under clinical trials for the treatment of ischemic brain diseases, it is found that the response 
caused by cyclic peptide binding was ～4-fold lower. The reduced binding activity of the 
cyclic peptide was further confirmed by an ELISA-based competitive binding assay, in which 
it shows that even at much higher concentrations, the cyclic peptide could not completely 
inhibit its linear counterpart, which showed strong binding affinity to PDZ2, to bind to PDZ2. 
Therefore, it is concluded from Chapter 2 that, SrtA-mediated synthesis of grafted cyclic 
peptide is efficient, and the produced grafted cyclic peptide shows remarkable stability and 
desired bioactivity, however, it shows reduced binding activity. With the aim to further 
address the inhibitory effect of the cyclic peptide in vitro as well as in vivo, and to optimize 
the cyclic peptide, the following work was carried out. 
To facilitate the evaluation of the inhibitory effect of the cyclic peptide in vivo, e.g. in 
mammalian cells, cyclic peptide was synthesized in mammalian cells rather than delivered 
into the cells. To facilitate the intracellular synthesis of cyclic peptide, sortase reaction was 
introduced to mammalian cells. 
In Chapter 3, an approach was developed to introduce sortase reaction to living 
mammalian cells for intracellular synthesis of cyclic grafted peptides. Transduction of 
Streptococcus pyogenes sortase A (SpSrtA) into mammalian cells by Bioporter reagent was 
confirmed, the function of transduced SpSrtA was analyzed, and the controllability of 
transduced SpSrtA-catalyzed reaction was studied.  
It is found that, our approach, by exogenously introducing SpSrtA to mammalian cells, is 
easily dose- and time-controllable and shows very low cytotoxicity, but has lower cyclization 
efficiency because the transduction amount of SpSrtA was confirmed to be lower, when 
comparing with the reported co-transfection method where both of SpSrtA and its substrate 
were introduced into cells via DNA transfection. Considering that cyclic peptides should be 
synthesized in relatively high yield to facilitate the evaluation of their inhibitory effect in vivo, 
therefore, the co-transfection method was selected for intracellular synthesis of cyclic grafted 
peptides. 
In Chapter 4, the strategy of “enzymatic synthesis of stable cyclic peptide-inhibitors of 
protein-protein interactions” was investigated in vivo. By using the approach decided in 
Chapter 3, peptide and SpSrtA were introduced into mammalian cells, and intracellular 
peptide cyclization catalyzed by SpSrtA was examined. It shows that, by using the strategy of 
sortase A-catalyzed peptide cyclization, production of grafted cyclic peptide in vivo is feasible, 
thus facilitating the screening of optimal cyclic peptide-inhibitors in vivo.  
In Chapter 5, the inhibitory potency of various cyclic peptides was evaluated by BRET 
assay. The possible reasons for the decreased binding activity were first explored. The crystal 
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structure of a peptide-complexed PDZ domain reveals that the peptide interacts with PDZ 
domain mainly via hydrogen bonds (H-bonds), importantly, the C-terminal valine plays a 
critical role in the interaction by forming four H-bonds via the carboxyl group and making 
Van der Waals contacts via the side chain. This provides one explanation for the reduced 
binding activity of the cyclic peptide grafted with ESDV sequence, as the carboxyl group of 
valine was lost after grafting. Other possibilities are also involved, considering that the 
binding pocket of PDZ domains has a relatively small surface area, whereas, the 
ESDV-grafted cyclic peptide has a relatively large size. Accordingly, the grafted peptide 
sequence as well as the grafting site needs to be optimized to improve the binding activity of 
the cyclic peptide. 
To improve the binding activity of cyclic peptides to PDZ2, different peptide sequences 
were designed by optimizing the grafting site as well as the grafted peptide sequence. The 
inhibitory effect of these cyclic peptides was first assessed by an in vitro BRET assay, where 
Rluc-PDZ2 and YPet-NR2B9c fusion proteins were mixed in the absence or presence of 
cyclic peptides; and except three cyclic peptides, which caused no or little reduction, the 
addition of other cyclic peptides caused a similar and significant reduction in BRET signal.  
The inhibitory potency of these cyclic peptides was further examined in a cellular 
context, which provides an ideal background for the selection of specific inhibitors, by a 
cell-based BRET assay, where Rluc-PDZ2 and YPet-NR2B9c fusions were co-expressed and 
the interaction between PDZ2 and NR2B9c enabled the generation of specific BRET signals. 
To introduce the cyclic peptides into cells co-expressing the BRET pairs, cells were 
co-transfected with the DNA of SpSrtA and the linear peptide precursors, and cyclic peptides 
were synthesized after SpSrtA-catalyzed cyclization. The inhibitory potency of the cyclic 
peptides can be reflected by the level of decrease in the BRET signal. It is demonstrated by 
the cell-based BRET assay that cells with cyclic peptides were detected with similar levels of 
BRET signal.  
However, when comparing the results of cell-based BRET assay with in vitro assay, 
inconsistency was observed. Considering that there are still some uncertainties with 
cell-based BRET assay, in vitro BRET assay thus is the better choice for the evaluation of the 
inhibitory effect of various peptides. Whereas, taking into account of the attractive advantages 
of cell-based BRET assay, for instance, cellular environment provides the ideal background 
for the selection of specific inhibitors as well as it is cost effective because cyclic peptides 
don’t need to be chemically synthesized, cell-based BRET assay will be improved for future 
use. 
Finally, to account for the differences in the binding activity of various cyclic peptides, 
the binding mode of different cyclic peptides to PDZ2 binding pocket was modeled. However, 
about two thirds of the modeling were unsuccessful; meanwhile, as the modeling was 
conducted in vacuum state, it’s possible that the modeled binding mode is very different from 
reality, as a result, more complete studies, e.g. molecular docking, need to be performed to 
explore the binding modes of different cyclic peptides to PDZ2, thus interpreting their 
difference in inhibitory potency.  
In Chapter 6, a conclusion of my study was made, and future prospect was described.  
In summary, by employing the combined strategy of peptide grafting into the scaffold of 
natural cyclic peptides and SrtA-catalyzed synthesis of grafted cyclic peptides, cyclic peptides 
 4 
with remarkable stability and desired inhibitory activity can be generated; production of such 
cyclic peptides is efficient in vitro and feasible in vivo, thus facilitating the screening of 
optimal cyclic peptide-inhibitors. In addition, BRET assay is a useful tool to evaluate the 
inhibitory effect of various cyclic peptides in vitro and in vivo.  
In spite of the above favorable findings, there are still some issues to be solved, for 
instance, cyclic peptides generated in living cells should be quantified in order to more clearly 
assess and compare their inhibitory potency; the expression levels of the BRET pairs should 
be fixed by using stably expressing cell lines or normalized to keep the expression levels of 
BRET pairs consistent among different assays.   
In the future, to obtain optimal cyclic peptide-inhibitors, library screening will be 
performed by combining virtual screening, e.g. molecular docking-based, and biological 
evaluation, e.g. by BRET assay.  
Meanwhile, other bioactive peptides, which are involved in diseases like angiogenesis, 
can be stabilized by using the same strategy, grafting the sequences into the framework of 
naturally occurring cyclic peptides like SFTI-1. The grafting site as well as grafted sequence 
can be further optimized under the guidance of computationally simulated interaction studies, 
to seek for potential drug leads for the treatment of diseases. Furthermore, the functional 
activities and selectivity of the potential drug leads can be assessed based on the validated 
BRET assays.  
 
